NCT00461006View on ClinicalTrials.gov

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Actos

45mg po daily

DRUG

aleglitazar

0.6mg po daily

Trial Locations (52)

2091

Kiev

2125

Kiev

11650

Mexico City

14000

Mexico City

14050

Mexico City

16602

Altoona

23510

Norfolk

28211

Charlotte

31238

Chihuahua City

31328

Chihuahua City

36024

Poltava

43302

Marion

45200

Zapopan

46002

Ternopil

49005

Dnipro

49060

Dnipro

61039

Kharkiv

61178

Kharkiv

64000

Monterrey

68131

Omaha

72401

Jonesboro

75231

Dallas

76014

Arlington

76017

Arlington

78284

San Antonio

79707

Midland

83003

Donetsk

83067

Hermosillo

83114

Donetsk

85381

Peoria

91045

Lugnansk

92691

Mission Viejo

93720

Fresno

95032

Los Gatos

109472

Moscow

125101

Moscow

127299

Moscow

127486

Moscow

129110

Moscow

150062

Yaroslavl

191025

Saint Petersburg

197198

Saint Petersburg

198205

Saint Petersburg

199106

Saint Petersburg

410038

Saratov

625023

Tyumen

32216-4313

Jacksonville

EMEX52140

Metepec

00674

Manatí

00717-322

Ponce

00949

Toa Baja

02091

Kiev

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00461006 - A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter